Top

Published in:

Open Access 01-12-2012 | Research article

Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia

Authors: Marcela Braga Mansur, Rocio Hassan, Thayana C Barbosa, Alessandra Splendore, Patricia Y Jotta, José Andrés Yunes, Joseph L Wiemels, Maria S Pombo-de-Oliveira

Published in: BMC Cancer | Issue 1/2012

Abstract

Background

Molecular alterations occur frequently in T-ALL and the potential impact of those abnormalities on outcome is still controversial. The current study aimed to test whether NOTCH1 mutations and additional molecular abnormalities would impact T-ALL outcome in a series of 138 T-ALL paediatric cases.

Methods

T-ALL subtypes, status of SIL-TAL1 fusion, ectopic expression of TLX3, and mutations in FBXW7, KRAS, PTEN and NOTCH1 were assessed as overall survival (OS) and event-free survival (EFS) prognostic factors. OS and EFS were determined using the Kaplan-Meier method and compared using the log-rank test.

Results

The frequencies of mutations were 43.5% for NOTCH1, while FBXW7, KRAS and PTEN exhibited frequencies of 19.1%, 9.5% and 9.4%, respectively. In 78.3% of cases, the coexistence of NOTCH1 mutations and other molecular alterations was observed. In multivariate analysis no statistical association was revealed between NOTCH1 mutations and any other variable analyzed. The mean length of the follow-up was 68.4 months and the OS was 50.7%. SIL-TAL1 was identified as an adverse prognostic factor. NOTCH1 mutation status was not associated with outcome, while the presence of NOTCH1 complex mutations (indels) were associated with a longer overall survival (p = 0.031) than point mutations.

Conclusion

NOTCH1 mutations alone or in combination with FBXW7 did not impact T-ALL prognosis. Nevertheless, complex NOTCH1 mutations appear to have a positive impact on OS and the SIL-TAL1 fusion was validated as a negative prognostic marker in our series of T-ALL.

Available only for authorised users

Aifantis I, Raetz E, Buonamici S: Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol. 2008, 8 (5): 380-390. 10.1038/nri2304.CrossRefPubMed

Pui CH, Robison LL, Look AT: Acute lymphoblastic leukaemia. Lancet. 2008, 371 (9617): 1030-1043. 10.1016/S0140-6736(08)60457-2.CrossRefPubMed

Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G, Happich M, Muckenthaler MU, Kulozik AE: Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood. 2006, 108 (4): 1151-1157. 10.1182/blood-2005-12-4956.CrossRefPubMed

Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH, Rowe JM, Caligiuri MA, Bloomfield CD, Look AT: Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet. 2004, 363 (9408): 535-536. 10.1016/S0140-6736(04)15542-6.CrossRefPubMed

Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, Behm FG, Pui CH, Downing JR, Gilliland DG, et al: Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002, 1 (1): 75-87. 10.1016/S1535-6108(02)00018-1.CrossRefPubMed

Mansur MB, Emerenciano M, Brewer L, Sant'Ana M, Mendonca N, Thuler LC, Koifman S, Pombo-de-Oliveira MS: SIL-TAL1 fusion gene negative impact in T-cell acute lymphoblastic leukemia outcome. Leuk Lymphoma. 2009, 50 (8): 1318-1325. 10.1080/10428190903040014.CrossRefPubMed

Aster JC, Blacklow SC, Pear WS: Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol. 2011, 223 (2): 262-273.CrossRefPubMed

Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J: TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991, 66 (4): 649-661. 10.1016/0092-8674(91)90111-B.CrossRefPubMed

Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004, 306 (5694): 269-271. 10.1126/science.1102160.CrossRefPubMed

10.

Grabher C, von Boehmer H, Look AT: Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2006, 6 (5): 347-359. 10.1038/nrc1880.CrossRefPubMed

11.

Mullighan CG: Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia. Haematologica. 2009, 94 (10): 1338-1340. 10.3324/haematol.2009.012047.CrossRefPubMedPubMedCentral

12.

Pombo de Oliveira MS, Koifman S, Vasconcelos GM, Emerenciano M, de Oliveira Novaes C: Development and perspective of current Brazilian studies on the epidemiology of childhood leukemia. Blood Cells Mol Dis. 2009, 42 (2): 121-125. 10.1016/j.bcmd.2008.10.012.CrossRefPubMed

13.

World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer -IARC, 2001. Edited by: Jaffe ES, Harris NL, Stein H, Vardiman JW. 2001, Lyon: IARC Press

14.

World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Edited by: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008, Lyon: IARC

15.

Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD: Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA. 2003, 100 (1): 177-182. 10.1073/pnas.0126614100.CrossRefPubMed

16.

Brandalise SR, Pinheiro VR, Aguiar SS, Matsuda EI, Otubo R, Yunes JA, Pereira WV, Carvalho EG, Cristofani LM, Souza MS, et al: Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian childhood cooperative group--protocol ALL-99. J Clin Oncol. 2010, 28 (11): 1911-1918. 10.1200/JCO.2009.25.6115.CrossRefPubMed

17.

Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, et al: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010, 24 (2): 265-284. 10.1038/leu.2009.257.CrossRefPubMed

18.

Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB: Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995, 9 (10): 1783-1786.PubMed

19.

Clappier E, Collette S, Grardel N, Girard S, Suarez L, Brunie G, Kaltenbach S, Yakouben K, Mazingue F, Robert A, et al: NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia. 2010, 24 (12): 2023-2031. 10.1038/leu.2010.205.CrossRefPubMed

20.

Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, Ludwig WD, Koehler R, Tolle G, Bandapalli OR, Breit S, et al: The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia. 2010, 24 (12): 2005-2013. 10.1038/leu.2010.203.CrossRefPubMedPubMedCentral

21.

Bernard OA, Busson-LeConiat M, Ballerini P, Mauchauffe M, Della Valle V, Monni R, Nguyen Khac F, Mercher T, Penard-Lacronique V, Pasturaud P, et al: A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia. 2001, 15 (10): 1495-1504. 10.1038/sj.leu.2402249.CrossRefPubMed

22.

van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, et al: Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999, 13 (12): 1901-1928. 10.1038/sj.leu.2401592.CrossRefPubMed

23.

Bornholdt J, Hansen J, Steiniche T, Dictor M, Antonsen A, Wolff H, Schlunssen V, Holmila R, Luce D, Vogel U, et al: K-ras mutations in sinonasal cancers in relation to wood dust exposure. BMC Cancer. 2008, 8: 53-10.1186/1471-2407-8-53.CrossRefPubMedPubMedCentral

24.

Jotta PY, Ganazza MA, Silva A, Viana MB, da Silva MJ, Zambaldi LJ, Barata JT, Brandalise SR, Yunes JA: Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia. 2010, 24 (1): 239-242. 10.1038/leu.2009.209.CrossRefPubMed

25.

van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, Burger NB, Passier M, van Lieshout EM, Kamps WA, et al: Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia. 2008, 22 (1): 124-131. 10.1038/sj.leu.2404957.CrossRefPubMed

26.

Meijerink JP: Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2010, 23 (3): 307-318. 10.1016/j.beha.2010.08.002.CrossRefPubMed

27.

Paganin M, Ferrando A: Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev. 2011, 25 (2): 83-90. 10.1016/j.blre.2010.09.004.CrossRefPubMed

28.

Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFiura K, Haska CL, Cherian C, Devidas M, Linda SB, Taub JW, et al: The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia. 2009, 23 (8): 1417-1425. 10.1038/leu.2009.64.CrossRefPubMed

29.

Park MJ, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R, Suzuki N, Hara J, Horibe K, Hayashi Y: FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol. 2009, 145 (2): 198-206. 10.1111/j.1365-2141.2009.07607.x.CrossRefPubMed

30.

Zhu YM, Zhao WL, Fu JF, Shi JY, Pan Q, Hu J, Gao XD, Chen B, Li JM, Xiong SM, et al: NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res. 2006, 12 (10): 3043-3049. 10.1158/1078-0432.CCR-05-2832.CrossRefPubMed

31.

Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, Kang HC, Kogan SC, Shokat K, Wolff L, et al: Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci USA. 2010, 107 (11): 5106-5111. 10.1073/pnas.1001064107.CrossRefPubMedPubMedCentral

32.

Kindler T, Cornejo MG, Scholl C, Liu J, Leeman DS, Haydu JE, Frohling S, Lee BH, Gilliland DG: K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood. 2008, 112 (8): 3373-3382. 10.1182/blood-2008-03-147587.CrossRefPubMedPubMedCentral

33.

Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, et al: Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007, 13 (10): 1203-1210. 10.1038/nm1636.CrossRefPubMedPubMedCentral

34.

Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, et al: High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009, 114 (3): 647-650. 10.1182/blood-2009-02-206722.CrossRefPubMedPubMedCentral

35.

O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters R, et al: FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007, 204 (8): 1813-1824. 10.1084/jem.20070876.CrossRefPubMedPubMedCentral

36.

Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G, Ferrando A, Aifantis I: The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med. 2007, 204 (8): 1825-1835. 10.1084/jem.20070872.CrossRefPubMedPubMedCentral

37.

Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JG, Kooi C, Smits WK, Sonneveld E, Veerman AJ, Kamps WA, et al: NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia. 2010, 24 (12): 2014-2022. 10.1038/leu.2010.204.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/9/prepub

Title: Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia
Authors: Marcela Braga Mansur
Rocio Hassan
Thayana C Barbosa
Alessandra Splendore
Patricia Y Jotta
José Andrés Yunes
Joseph L Wiemels
Maria S Pombo-de-Oliveira
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-12-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

Nuclear expression of Rac1 in cervical premalignant lesions and cervical cancer cells

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma

Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells

Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis

aThe dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer